Gregory W Charville
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (28)
Case: An 18-year-old man with no significant medical history presented with persistent anterior knee pain. Imaging revealed multifocal marrow-replacing lesions in the distal femur and patella. Open biopsy confirmed the diagnosis of pseudomyogenic hemangioendothelioma. Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography showed intense multifocal hypermetabolism (SUVmax 13.8). Surgery was deferred due to morbidity, so the patient was treated with intravenous zoledronic acid, resulting in clinical improvement and sustained radiographic and metabolic response over 18 months (SUVmax reduced to 2.26). Conclusion: This case highlights a durable radiographic and clinical response to zoledronic acid monotherapy in multifocal pseudomyogenic hemangioendothelioma, supporting its role as a function-preserving systemic therapy.
Year:
2025
Shows biophysical and biochemical assays, including SPR, GST pulldown, streptavidin pulldown, and TR-FRET, demonstrating compound-induced interactions between TRIM21 and NUP98, and a schematic of the molecular glue mechanism.
Year:
2025
Cancer cells are acutely dependent on nuclear transport due to elevated transcriptional activity, suggesting an unrealized opportunity for selective therapeutic inhibition of the nuclear pore complex (NPC). Through large-scale phenotypic profiling of cancer cell lines, genome-scale functional genomic modifier screens, and mass spectrometry–based proteomics, we discovered that the clinical drug PRLX-93936 is a molecular glue that binds and reprograms the TRIM21 ubiquitin ligase to degrade the NPC. Upon compound-induced TRIM21 recruitment, the nuclear pore is ubiquitylated and degraded, resulting in the loss of short-lived cytoplasmic mRNA transcripts and the induction of cancer cell apoptosis. Direct compound binding to TRIM21 was confirmed via surface plasmon resonance and X-ray crystallography, whereas compound-induced TRIM21–nucleoporin complex formation was demonstrated through multiple orthogonal approaches in cells and in vitro . Phenotype-guided optimization yielded compounds with 10-fold greater potency and drug-like properties, along with robust pharmacokinetics and efficacy against pancreatic cancer xenografts and patient-derived organoids. Significance: This study establishes the cancer therapeutic potential of optimized TRIM21 molecular glues to degrade the NPC and underscores the value of reexamining drugs with previously unknown mechanisms using current technologies.
Year:
2025
Shows proteomic and imaging analyses demonstrating TRIM21-dependent rapid degradation of nuclear pore complex proteins by PRLX and JWZ-8-103, including LC-MS/MS profiling, structural mapping, and confocal microscopy.
Year:
2025
Presents pharmacokinetic analyses and in vivo efficacy of TRIM21-targeting compounds in organoid and xenograft models, including immunoblotting, plasma concentration profiles, and tumor growth studies.
Year:
2025
Depicts live-cell imaging, lethal fraction analyses, and protein interaction/immunoblot assays demonstrating TRIM21-dependent PRLX-induced nucleoporin destabilization and rapid cancer cell death.
Year:
2025
Insulinoma-associated protein 1 (INSM1) is a relatively new immunostain used in the diagnostic assessment of tumors with neuroendocrine differentiation. While INSM1 positivity has been described in some non-neuroendocrine neoplasms, reactivity in red blood cells (RBCs) has only been anecdotally noted in one prior study without description of the degree/extent of staining. INSM1 staining in nucleated erythroid precursors has not been previously reported. Herein, 100 small biopsy specimens containing RBCs where INSM1 was used for diagnostic workup were reviewed. Additionally, 5 benign bone specimens and 5 adrenal myelolipoma specimens containing nucleated erythroid precursors were stained with INSM1. INSM1 staining intensity (0–3) and staining extent (0–100%) in RBC/erythroid cells was evaluated and an H-score was calculated (0–300). Positive cytoplasmic INSM1 staining in RBCs was observed in 99/100 (99%) specimens, with mean staining intensity of 2.1 (median = 2) and mean staining percent of 59% (median = 70%), with mean H-score of 125 (median = 140). Positive cytoplasmic INSM1 staining was identified in 10/10 (100%) specimens containing nucleated erythroid precursors, with mean staining intensity of 2.7 (median = 3) and mean staining percent of 53% (median = 50%), with mean H-score of 132 (median = 120). INSM1 is frequently positive in RBCs and nucleated erythroid precursors, albeit with variable staining intensity and extent. Although the INSM1 staining is cytoplasmic in RBCs (lacking nuclei) and nucleated erythroid precursors, the morphological features can mimic positive nuclear staining of neuroendocrine neoplasms. Particularly in small biopsy samples, which often contain background RBCs, positive INSM1 staining should be reviewed with caution to avoid misdiagnosis of neuroendocrine differentiation.
Year:
2025
Supplementary Table 14. Variant allele fraction of clonal and subclonal point mutations supported by RNA-seq reads in Patient 2 (in genomic positions supported by >10 reads coverage and present in both forward and reverse reads).
Year:
2025
Supplementary Table 13. Variant allele fraction of clonal and subclonal point mutations supported by RNA-seq reads in Patient 1 (in genomic positions supported by >10 reads coverage and present in both forward and reverse reads).
Year:
2025
Supplementary Table 10. Summary of selected clinicopathological features of patient cohorts in the present study (De Bellis et al.) and in the previous studies published by Salas et al. and Kohsaka et al.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (29)
Timothy Sears
University of California, San Diego
Wenzhi Ji
Post/staff Scientist
Stanford University
Benjamin Haibe-Kains
University of Toronto
Matt van de Rijn
prof
Stanford University
Garry Nolan
Professor and Carlota A. Harris Professor
Stanford University School of Medicine
Aaron Newman
Associate Professor
Stanford University
Guolan Lu
Assistant Professor
Stanford University
Ulrike Peters
Fred Hutchinson Cancer Research Center
Everett J. Moding
Stanford University
Cooper Rutland
Clinical Assistant Professor
University of Michigan
James Zou
Stanford University
Stephen Hinshaw
Stanford University
Robert B. West
Stanford University School of Medicine
Zhenqin Wu
Assistant Professor
The University of Hong Kong
Scott Dixon
Associate Professor
Stanford University
Hans-Christoph Becker
Professor
Stanford University School of Medicine
Ankur R. Sangoi
Stanford University
Marta Lohman, DVM
Stanford University
Deana Colburg
Stanford University
Justin M M Cates
Professor
Wake Forest Baptist Medical Center
Kristen N. Ganjoo
Stanford University School of Medicine
Calvin Kuo
Professor
Stanford University
Steven Corsello
Stanford University
John Hickey
Assistant Professor
Duke University
Nathanael S. Gray
Stanford University
Christopher Li
Fred Hutchinson Cancer Research Center
Jeanne Shen
Associate Professor
Stanford University
Jennifer Roth
Broad Institute
Kyle Loh
Associate Professor and The Anthony DiGenova Endowed Faculty Scholar
Stanford University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.